Stay updated on Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded UI/metadata updates: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check19 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedLocation information updated: a new Locations heading appears and specific state sites (Georgia, Illinois, New Jersey, New York) are listed. State-specific subsections were removed, and the revision updated to v3.3.3.SummaryDifference0.5%

- Check69 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 with no visible changes to content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check76 days agoChange DetectedMinor administrative updates: a note stating that publications are automatically filled from PubMed and a new Revision: v3.3.1; these changes do not affect the study details, and to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedRemoved the general government funding/operating status notice from the page; study details remain unchanged.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Hodgkin Lymphoma Clinical Trial page.